ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Transdermal Therapeutic Systems (TTS) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Published Date: October 2024
|
Report Code: QYRE-Auto-3M13690
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Transdermal Therapeutic Systems TTS Market Research Report 2023
BUY CHAPTERS

Transdermal Therapeutic Systems (TTS) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-3M13690
Report
October 2024
Pages:167
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Hisamitsu
Mylan NV
GSK
Novartis
Teve (Actavis)
Nitto Denko
Johnson & Johnson
Lohmann
TEIKOKU SEIYAKU
Pfizer Inc
Bayer
Lingrui
Sanofi
UCB Pharma
Dr. Reddy’s Laboratories
Qizheng
Endo
Mundipharma
Huarun 999
Haw Par
Nichiban
Mentholatum Company
Laboratoires Genevrier
Beijing Tide Pharmaceutical
Luye Pharma Group

Transdermal Therapeutic Systems (TTS) - Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Transdermal Therapeutic Systems (TTS) - Market

Transdermal Therapeutic Systems (TTS) - Market

Transdermal Therapeutic Systems (TTS) is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. Often, this promotes healing to an injured area of the body. An advantage of a transdermal drug delivery route over other types of medication delivery such as oral, topical, intravenous, intramuscular, etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive.
The global market for Transdermal Therapeutic Systems (TTS) was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Transdermal Therapeutic Systems (TTS), focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Transdermal Therapeutic Systems (TTS) by region & country, by Type, and by Application.
The Transdermal Therapeutic Systems (TTS) market size, estimations, and forecasts are provided in terms of sales volume (M Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Transdermal Therapeutic Systems (TTS).
Market Segmentation

Scope of Transdermal Therapeutic Systems (TTS) - Market Report

Report Metric Details
Report Name Transdermal Therapeutic Systems (TTS) - Market
CAGR 5%
Segment by Type:
  • Methyl Salicylate
  • Nitroglycerin
  • Fentanyl
  • Nicotine
  • Rivastigmine
  • Estradiol
  • Others
Segment by Application
  • OTC Channel
  • Retail Channel
  • E-Commerce Channel
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Hisamitsu, Mylan, GSK, Novartis, Teve (Actavis), Nitto Denko, Johnson & Johnson, Lohmann, Teikoku Seiyaku, Pfizer, Bayer, Lingrui, Sanofi, UCB Pharma, Dr. Reddy's Laboratories, Qizheng, Endo, Mundipharma, Huarun 999, Haw Par, Nichiban, Mentholatum Company, Laboratoires Genevrier, Beijing Tide Pharmaceutical, Luye Pharma Group
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Transdermal Therapeutic Systems (TTS) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Sales, revenue of Transdermal Therapeutic Systems (TTS) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Sales, revenue of Transdermal Therapeutic Systems (TTS) in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Transdermal Therapeutic Systems (TTS) - Market report?

Ans: The main players in the Transdermal Therapeutic Systems (TTS) - Market are Hisamitsu, Mylan, GSK, Novartis, Teve (Actavis), Nitto Denko, Johnson & Johnson, Lohmann, Teikoku Seiyaku, Pfizer, Bayer, Lingrui, Sanofi, UCB Pharma, Dr. Reddy's Laboratories, Qizheng, Endo, Mundipharma, Huarun 999, Haw Par, Nichiban, Mentholatum Company, Laboratoires Genevrier, Beijing Tide Pharmaceutical, Luye Pharma Group

What are the Application segmentation covered in the Transdermal Therapeutic Systems (TTS) - Market report?

Ans: The Applications covered in the Transdermal Therapeutic Systems (TTS) - Market report are OTC Channel, Retail Channel, E-Commerce Channel

What are the Type segmentation covered in the Transdermal Therapeutic Systems (TTS) - Market report?

Ans: The Types covered in the Transdermal Therapeutic Systems (TTS) - Market report are Methyl Salicylate, Nitroglycerin, Fentanyl, Nicotine, Rivastigmine, Estradiol, Others

1 Market Overview
1.1 Transdermal Therapeutic Systems (TTS) Product Introduction
1.2 Global Transdermal Therapeutic Systems (TTS) Market Size Forecast
1.2.1 Global Transdermal Therapeutic Systems (TTS) Sales Value (2019-2030)
1.2.2 Global Transdermal Therapeutic Systems (TTS) Sales Volume (2019-2030)
1.2.3 Global Transdermal Therapeutic Systems (TTS) Sales Price (2019-2030)
1.3 Transdermal Therapeutic Systems (TTS) Market Trends & Drivers
1.3.1 Transdermal Therapeutic Systems (TTS) Industry Trends
1.3.2 Transdermal Therapeutic Systems (TTS) Market Drivers & Opportunity
1.3.3 Transdermal Therapeutic Systems (TTS) Market Challenges
1.3.4 Transdermal Therapeutic Systems (TTS) Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Transdermal Therapeutic Systems (TTS) Players Revenue Ranking (2023)
2.2 Global Transdermal Therapeutic Systems (TTS) Revenue by Company (2019-2024)
2.3 Global Transdermal Therapeutic Systems (TTS) Players Sales Volume Ranking (2023)
2.4 Global Transdermal Therapeutic Systems (TTS) Sales Volume by Company Players (2019-2024)
2.5 Global Transdermal Therapeutic Systems (TTS) Average Price by Company (2019-2024)
2.6 Key Manufacturers Transdermal Therapeutic Systems (TTS) Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Transdermal Therapeutic Systems (TTS) Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Transdermal Therapeutic Systems (TTS)
2.9 Transdermal Therapeutic Systems (TTS) Market Competitive Analysis
2.9.1 Transdermal Therapeutic Systems (TTS) Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Transdermal Therapeutic Systems (TTS) Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transdermal Therapeutic Systems (TTS) as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Methyl Salicylate
3.1.2 Nitroglycerin
3.1.3 Fentanyl
3.1.4 Nicotine
3.1.5 Rivastigmine
3.1.6 Estradiol
3.1.7 Others
3.2 Global Transdermal Therapeutic Systems (TTS) Sales Value by Type
3.2.1 Global Transdermal Therapeutic Systems (TTS) Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Transdermal Therapeutic Systems (TTS) Sales Value, by Type (2019-2030)
3.2.3 Global Transdermal Therapeutic Systems (TTS) Sales Value, by Type (%) (2019-2030)
3.3 Global Transdermal Therapeutic Systems (TTS) Sales Volume by Type
3.3.1 Global Transdermal Therapeutic Systems (TTS) Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Transdermal Therapeutic Systems (TTS) Sales Volume, by Type (2019-2030)
3.3.3 Global Transdermal Therapeutic Systems (TTS) Sales Volume, by Type (%) (2019-2030)
3.4 Global Transdermal Therapeutic Systems (TTS) Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 OTC Channel
4.1.2 Retail Channel
4.1.3 E-Commerce Channel
4.2 Global Transdermal Therapeutic Systems (TTS) Sales Value by Application
4.2.1 Global Transdermal Therapeutic Systems (TTS) Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Transdermal Therapeutic Systems (TTS) Sales Value, by Application (2019-2030)
4.2.3 Global Transdermal Therapeutic Systems (TTS) Sales Value, by Application (%) (2019-2030)
4.3 Global Transdermal Therapeutic Systems (TTS) Sales Volume by Application
4.3.1 Global Transdermal Therapeutic Systems (TTS) Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Transdermal Therapeutic Systems (TTS) Sales Volume, by Application (2019-2030)
4.3.3 Global Transdermal Therapeutic Systems (TTS) Sales Volume, by Application (%) (2019-2030)
4.4 Global Transdermal Therapeutic Systems (TTS) Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Transdermal Therapeutic Systems (TTS) Sales Value by Region
5.1.1 Global Transdermal Therapeutic Systems (TTS) Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Transdermal Therapeutic Systems (TTS) Sales Value by Region (2019-2024)
5.1.3 Global Transdermal Therapeutic Systems (TTS) Sales Value by Region (2025-2030)
5.1.4 Global Transdermal Therapeutic Systems (TTS) Sales Value by Region (%), (2019-2030)
5.2 Global Transdermal Therapeutic Systems (TTS) Sales Volume by Region
5.2.1 Global Transdermal Therapeutic Systems (TTS) Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Transdermal Therapeutic Systems (TTS) Sales Volume by Region (2019-2024)
5.2.3 Global Transdermal Therapeutic Systems (TTS) Sales Volume by Region (2025-2030)
5.2.4 Global Transdermal Therapeutic Systems (TTS) Sales Volume by Region (%), (2019-2030)
5.3 Global Transdermal Therapeutic Systems (TTS) Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Transdermal Therapeutic Systems (TTS) Sales Value, 2019-2030
5.4.2 North America Transdermal Therapeutic Systems (TTS) Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Transdermal Therapeutic Systems (TTS) Sales Value, 2019-2030
5.5.2 Europe Transdermal Therapeutic Systems (TTS) Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Transdermal Therapeutic Systems (TTS) Sales Value, 2019-2030
5.6.2 Asia Pacific Transdermal Therapeutic Systems (TTS) Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Transdermal Therapeutic Systems (TTS) Sales Value, 2019-2030
5.7.2 South America Transdermal Therapeutic Systems (TTS) Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Transdermal Therapeutic Systems (TTS) Sales Value, 2019-2030
5.8.2 Middle East & Africa Transdermal Therapeutic Systems (TTS) Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Transdermal Therapeutic Systems (TTS) Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Transdermal Therapeutic Systems (TTS) Sales Value
6.2.1 Key Countries/Regions Transdermal Therapeutic Systems (TTS) Sales Value, 2019-2030
6.2.2 Key Countries/Regions Transdermal Therapeutic Systems (TTS) Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Transdermal Therapeutic Systems (TTS) Sales Value, 2019-2030
6.3.2 United States Transdermal Therapeutic Systems (TTS) Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Transdermal Therapeutic Systems (TTS) Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Transdermal Therapeutic Systems (TTS) Sales Value, 2019-2030
6.4.2 Europe Transdermal Therapeutic Systems (TTS) Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Transdermal Therapeutic Systems (TTS) Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Transdermal Therapeutic Systems (TTS) Sales Value, 2019-2030
6.5.2 China Transdermal Therapeutic Systems (TTS) Sales Value by Type (%), 2023 VS 2030
6.5.3 China Transdermal Therapeutic Systems (TTS) Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Transdermal Therapeutic Systems (TTS) Sales Value, 2019-2030
6.6.2 Japan Transdermal Therapeutic Systems (TTS) Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Transdermal Therapeutic Systems (TTS) Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Transdermal Therapeutic Systems (TTS) Sales Value, 2019-2030
6.7.2 South Korea Transdermal Therapeutic Systems (TTS) Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Transdermal Therapeutic Systems (TTS) Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Transdermal Therapeutic Systems (TTS) Sales Value, 2019-2030
6.8.2 Southeast Asia Transdermal Therapeutic Systems (TTS) Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Transdermal Therapeutic Systems (TTS) Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Transdermal Therapeutic Systems (TTS) Sales Value, 2019-2030
6.9.2 India Transdermal Therapeutic Systems (TTS) Sales Value by Type (%), 2023 VS 2030
6.9.3 India Transdermal Therapeutic Systems (TTS) Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Hisamitsu
7.1.1 Hisamitsu Company Information
7.1.2 Hisamitsu Introduction and Business Overview
7.1.3 Hisamitsu Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Hisamitsu Transdermal Therapeutic Systems (TTS) Product Offerings
7.1.5 Hisamitsu Recent Development
7.2 Mylan
7.2.1 Mylan Company Information
7.2.2 Mylan Introduction and Business Overview
7.2.3 Mylan Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Mylan Transdermal Therapeutic Systems (TTS) Product Offerings
7.2.5 Mylan Recent Development
7.3 GSK
7.3.1 GSK Company Information
7.3.2 GSK Introduction and Business Overview
7.3.3 GSK Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2019-2024)
7.3.4 GSK Transdermal Therapeutic Systems (TTS) Product Offerings
7.3.5 GSK Recent Development
7.4 Novartis
7.4.1 Novartis Company Information
7.4.2 Novartis Introduction and Business Overview
7.4.3 Novartis Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Novartis Transdermal Therapeutic Systems (TTS) Product Offerings
7.4.5 Novartis Recent Development
7.5 Teve (Actavis)
7.5.1 Teve (Actavis) Company Information
7.5.2 Teve (Actavis) Introduction and Business Overview
7.5.3 Teve (Actavis) Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Teve (Actavis) Transdermal Therapeutic Systems (TTS) Product Offerings
7.5.5 Teve (Actavis) Recent Development
7.6 Nitto Denko
7.6.1 Nitto Denko Company Information
7.6.2 Nitto Denko Introduction and Business Overview
7.6.3 Nitto Denko Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Nitto Denko Transdermal Therapeutic Systems (TTS) Product Offerings
7.6.5 Nitto Denko Recent Development
7.7 Johnson & Johnson
7.7.1 Johnson & Johnson Company Information
7.7.2 Johnson & Johnson Introduction and Business Overview
7.7.3 Johnson & Johnson Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Johnson & Johnson Transdermal Therapeutic Systems (TTS) Product Offerings
7.7.5 Johnson & Johnson Recent Development
7.8 Lohmann
7.8.1 Lohmann Company Information
7.8.2 Lohmann Introduction and Business Overview
7.8.3 Lohmann Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Lohmann Transdermal Therapeutic Systems (TTS) Product Offerings
7.8.5 Lohmann Recent Development
7.9 Teikoku Seiyaku
7.9.1 Teikoku Seiyaku Company Information
7.9.2 Teikoku Seiyaku Introduction and Business Overview
7.9.3 Teikoku Seiyaku Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Teikoku Seiyaku Transdermal Therapeutic Systems (TTS) Product Offerings
7.9.5 Teikoku Seiyaku Recent Development
7.10 Pfizer
7.10.1 Pfizer Company Information
7.10.2 Pfizer Introduction and Business Overview
7.10.3 Pfizer Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Pfizer Transdermal Therapeutic Systems (TTS) Product Offerings
7.10.5 Pfizer Recent Development
7.11 Bayer
7.11.1 Bayer Company Information
7.11.2 Bayer Introduction and Business Overview
7.11.3 Bayer Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Bayer Transdermal Therapeutic Systems (TTS) Product Offerings
7.11.5 Bayer Recent Development
7.12 Lingrui
7.12.1 Lingrui Company Information
7.12.2 Lingrui Introduction and Business Overview
7.12.3 Lingrui Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Lingrui Transdermal Therapeutic Systems (TTS) Product Offerings
7.12.5 Lingrui Recent Development
7.13 Sanofi
7.13.1 Sanofi Company Information
7.13.2 Sanofi Introduction and Business Overview
7.13.3 Sanofi Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Sanofi Transdermal Therapeutic Systems (TTS) Product Offerings
7.13.5 Sanofi Recent Development
7.14 UCB Pharma
7.14.1 UCB Pharma Company Information
7.14.2 UCB Pharma Introduction and Business Overview
7.14.3 UCB Pharma Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2019-2024)
7.14.4 UCB Pharma Transdermal Therapeutic Systems (TTS) Product Offerings
7.14.5 UCB Pharma Recent Development
7.15 Dr. Reddy's Laboratories
7.15.1 Dr. Reddy's Laboratories Company Information
7.15.2 Dr. Reddy's Laboratories Introduction and Business Overview
7.15.3 Dr. Reddy's Laboratories Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Dr. Reddy's Laboratories Transdermal Therapeutic Systems (TTS) Product Offerings
7.15.5 Dr. Reddy's Laboratories Recent Development
7.16 Qizheng
7.16.1 Qizheng Company Information
7.16.2 Qizheng Introduction and Business Overview
7.16.3 Qizheng Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2019-2024)
7.16.4 Qizheng Transdermal Therapeutic Systems (TTS) Product Offerings
7.16.5 Qizheng Recent Development
7.17 Endo
7.17.1 Endo Company Information
7.17.2 Endo Introduction and Business Overview
7.17.3 Endo Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2019-2024)
7.17.4 Endo Transdermal Therapeutic Systems (TTS) Product Offerings
7.17.5 Endo Recent Development
7.18 Mundipharma
7.18.1 Mundipharma Company Information
7.18.2 Mundipharma Introduction and Business Overview
7.18.3 Mundipharma Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2019-2024)
7.18.4 Mundipharma Transdermal Therapeutic Systems (TTS) Product Offerings
7.18.5 Mundipharma Recent Development
7.19 Huarun 999
7.19.1 Huarun 999 Company Information
7.19.2 Huarun 999 Introduction and Business Overview
7.19.3 Huarun 999 Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2019-2024)
7.19.4 Huarun 999 Transdermal Therapeutic Systems (TTS) Product Offerings
7.19.5 Huarun 999 Recent Development
7.20 Haw Par
7.20.1 Haw Par Company Information
7.20.2 Haw Par Introduction and Business Overview
7.20.3 Haw Par Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2019-2024)
7.20.4 Haw Par Transdermal Therapeutic Systems (TTS) Product Offerings
7.20.5 Haw Par Recent Development
7.21 Nichiban
7.21.1 Nichiban Company Information
7.21.2 Nichiban Introduction and Business Overview
7.21.3 Nichiban Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2019-2024)
7.21.4 Nichiban Transdermal Therapeutic Systems (TTS) Product Offerings
7.21.5 Nichiban Recent Development
7.22 Mentholatum Company
7.22.1 Mentholatum Company Company Information
7.22.2 Mentholatum Company Introduction and Business Overview
7.22.3 Mentholatum Company Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2019-2024)
7.22.4 Mentholatum Company Transdermal Therapeutic Systems (TTS) Product Offerings
7.22.5 Mentholatum Company Recent Development
7.23 Laboratoires Genevrier
7.23.1 Laboratoires Genevrier Company Information
7.23.2 Laboratoires Genevrier Introduction and Business Overview
7.23.3 Laboratoires Genevrier Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2019-2024)
7.23.4 Laboratoires Genevrier Transdermal Therapeutic Systems (TTS) Product Offerings
7.23.5 Laboratoires Genevrier Recent Development
7.24 Beijing Tide Pharmaceutical
7.24.1 Beijing Tide Pharmaceutical Company Information
7.24.2 Beijing Tide Pharmaceutical Introduction and Business Overview
7.24.3 Beijing Tide Pharmaceutical Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2019-2024)
7.24.4 Beijing Tide Pharmaceutical Transdermal Therapeutic Systems (TTS) Product Offerings
7.24.5 Beijing Tide Pharmaceutical Recent Development
7.25 Luye Pharma Group
7.25.1 Luye Pharma Group Company Information
7.25.2 Luye Pharma Group Introduction and Business Overview
7.25.3 Luye Pharma Group Transdermal Therapeutic Systems (TTS) Sales, Revenue and Gross Margin (2019-2024)
7.25.4 Luye Pharma Group Transdermal Therapeutic Systems (TTS) Product Offerings
7.25.5 Luye Pharma Group Recent Development
8 Industry Chain Analysis
8.1 Transdermal Therapeutic Systems (TTS) Industrial Chain
8.2 Transdermal Therapeutic Systems (TTS) Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Transdermal Therapeutic Systems (TTS) Sales Model
8.5.2 Sales Channel
8.5.3 Transdermal Therapeutic Systems (TTS) Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
FEATURED COMPANIES
Hisamitsu
Mylan NV
GSK
Novartis
Teve (Actavis)
Nitto Denko
Johnson & Johnson
Lohmann
TEIKOKU SEIYAKU
Pfizer Inc
Bayer
Lingrui
Sanofi
UCB Pharma
Dr. Reddy’s Laboratories
Qizheng
Endo
Mundipharma
Huarun 999
Haw Par
Nichiban
Mentholatum Company
Laboratoires Genevrier
Beijing Tide Pharmaceutical
Luye Pharma Group
List of Tables
    Table 1. Transdermal Therapeutic Systems (TTS) Market Trends
    Table 2. Transdermal Therapeutic Systems (TTS) Market Drivers & Opportunity
    Table 3. Transdermal Therapeutic Systems (TTS) Market Challenges
    Table 4. Transdermal Therapeutic Systems (TTS) Market Restraints
    Table 5. Global Transdermal Therapeutic Systems (TTS) Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Transdermal Therapeutic Systems (TTS) Revenue Market Share by Company (2019-2024)
    Table 7. Global Transdermal Therapeutic Systems (TTS) Sales Volume by Company (2019-2024) & (M Units)
    Table 8. Global Transdermal Therapeutic Systems (TTS) Sales Volume Market Share by Company (2019-2024)
    Table 9. Global Market Transdermal Therapeutic Systems (TTS) Price by Company (2019-2024) & (USD/K Units)
    Table 10. Key Manufacturers Transdermal Therapeutic Systems (TTS) Manufacturing Base Distribution and Headquarters
    Table 11. Key Manufacturers Transdermal Therapeutic Systems (TTS) Product Type
    Table 12. Key Manufacturers Time to Begin Mass Production of Transdermal Therapeutic Systems (TTS)
    Table 13. Global Transdermal Therapeutic Systems (TTS) Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transdermal Therapeutic Systems (TTS) as of 2023)
    Table 15. Mergers & Acquisitions, Expansion Plans
    Table 16. Global Transdermal Therapeutic Systems (TTS) Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 17. Global Transdermal Therapeutic Systems (TTS) Sales Value by Type (2019-2024) & (US$ Million)
    Table 18. Global Transdermal Therapeutic Systems (TTS) Sales Value by Type (2025-2030) & (US$ Million)
    Table 19. Global Transdermal Therapeutic Systems (TTS) Sales Market Share in Value by Type (2019-2024) & (%)
    Table 20. Global Transdermal Therapeutic Systems (TTS) Sales Market Share in Value by Type (2025-2030) & (%)
    Table 21. Global Transdermal Therapeutic Systems (TTS) Sales Volume by Type: 2019 VS 2023 VS 2030 (M Units)
    Table 22. Global Transdermal Therapeutic Systems (TTS) Sales Volume by Type (2019-2024) & (M Units)
    Table 23. Global Transdermal Therapeutic Systems (TTS) Sales Volume by Type (2025-2030) & (M Units)
    Table 24. Global Transdermal Therapeutic Systems (TTS) Sales Market Share in Volume by Type (2019-2024) & (%)
    Table 25. Global Transdermal Therapeutic Systems (TTS) Sales Market Share in Volume by Type (2025-2030) & (%)
    Table 26. Global Transdermal Therapeutic Systems (TTS) Price by Type (2019-2024) & (USD/K Units)
    Table 27. Global Transdermal Therapeutic Systems (TTS) Price by Type (2025-2030) & (USD/K Units)
    Table 28. Global Transdermal Therapeutic Systems (TTS) Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 29. Global Transdermal Therapeutic Systems (TTS) Sales Value by Application (2019-2024) & (US$ Million)
    Table 30. Global Transdermal Therapeutic Systems (TTS) Sales Value by Application (2025-2030) & (US$ Million)
    Table 31. Global Transdermal Therapeutic Systems (TTS) Sales Market Share in Value by Application (2019-2024) & (%)
    Table 32. Global Transdermal Therapeutic Systems (TTS) Sales Market Share in Value by Application (2025-2030) & (%)
    Table 33. Global Transdermal Therapeutic Systems (TTS) Sales Volume by Application: 2019 VS 2023 VS 2030 (M Units)
    Table 34. Global Transdermal Therapeutic Systems (TTS) Sales Volume by Application (2019-2024) & (M Units)
    Table 35. Global Transdermal Therapeutic Systems (TTS) Sales Volume by Application (2025-2030) & (M Units)
    Table 36. Global Transdermal Therapeutic Systems (TTS) Sales Market Share in Volume by Application (2019-2024) & (%)
    Table 37. Global Transdermal Therapeutic Systems (TTS) Sales Market Share in Volume by Application (2025-2030) & (%)
    Table 38. Global Transdermal Therapeutic Systems (TTS) Price by Application (2019-2024) & (USD/K Units)
    Table 39. Global Transdermal Therapeutic Systems (TTS) Price by Application (2025-2030) & (USD/K Units)
    Table 40. Global Transdermal Therapeutic Systems (TTS) Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Global Transdermal Therapeutic Systems (TTS) Sales Value by Region (2019-2024) & (US$ Million)
    Table 42. Global Transdermal Therapeutic Systems (TTS) Sales Value by Region (2025-2030) & (US$ Million)
    Table 43. Global Transdermal Therapeutic Systems (TTS) Sales Value by Region (2019-2024) & (%)
    Table 44. Global Transdermal Therapeutic Systems (TTS) Sales Value by Region (2025-2030) & (%)
    Table 45. Global Transdermal Therapeutic Systems (TTS) Sales Volume by Region (M Units): 2019 VS 2023 VS 2030
    Table 46. Global Transdermal Therapeutic Systems (TTS) Sales Volume by Region (2019-2024) & (M Units)
    Table 47. Global Transdermal Therapeutic Systems (TTS) Sales Volume by Region (2025-2030) & (M Units)
    Table 48. Global Transdermal Therapeutic Systems (TTS) Sales Volume by Region (2019-2024) & (%)
    Table 49. Global Transdermal Therapeutic Systems (TTS) Sales Volume by Region (2025-2030) & (%)
    Table 50. Global Transdermal Therapeutic Systems (TTS) Average Price by Region (2019-2024) & (USD/K Units)
    Table 51. Global Transdermal Therapeutic Systems (TTS) Average Price by Region (2025-2030) & (USD/K Units)
    Table 52. Key Countries/Regions Transdermal Therapeutic Systems (TTS) Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 53. Key Countries/Regions Transdermal Therapeutic Systems (TTS) Sales Value, (2019-2024) & (US$ Million)
    Table 54. Key Countries/Regions Transdermal Therapeutic Systems (TTS) Sales Value, (2025-2030) & (US$ Million)
    Table 55. Key Countries/Regions Transdermal Therapeutic Systems (TTS) Sales Volume, (2019-2024) & (M Units)
    Table 56. Key Countries/Regions Transdermal Therapeutic Systems (TTS) Sales Volume, (2025-2030) & (M Units)
    Table 57. Hisamitsu Company Information
    Table 58. Hisamitsu Introduction and Business Overview
    Table 59. Hisamitsu Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (US$ Million), Price (USD/K Units) and Gross Margin (2019-2024)
    Table 60. Hisamitsu Transdermal Therapeutic Systems (TTS) Product Offerings
    Table 61. Hisamitsu Recent Development
    Table 62. Mylan Company Information
    Table 63. Mylan Introduction and Business Overview
    Table 64. Mylan Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (US$ Million), Price (USD/K Units) and Gross Margin (2019-2024)
    Table 65. Mylan Transdermal Therapeutic Systems (TTS) Product Offerings
    Table 66. Mylan Recent Development
    Table 67. GSK Company Information
    Table 68. GSK Introduction and Business Overview
    Table 69. GSK Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (US$ Million), Price (USD/K Units) and Gross Margin (2019-2024)
    Table 70. GSK Transdermal Therapeutic Systems (TTS) Product Offerings
    Table 71. GSK Recent Development
    Table 72. Novartis Company Information
    Table 73. Novartis Introduction and Business Overview
    Table 74. Novartis Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (US$ Million), Price (USD/K Units) and Gross Margin (2019-2024)
    Table 75. Novartis Transdermal Therapeutic Systems (TTS) Product Offerings
    Table 76. Novartis Recent Development
    Table 77. Teve (Actavis) Company Information
    Table 78. Teve (Actavis) Introduction and Business Overview
    Table 79. Teve (Actavis) Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (US$ Million), Price (USD/K Units) and Gross Margin (2019-2024)
    Table 80. Teve (Actavis) Transdermal Therapeutic Systems (TTS) Product Offerings
    Table 81. Teve (Actavis) Recent Development
    Table 82. Nitto Denko Company Information
    Table 83. Nitto Denko Introduction and Business Overview
    Table 84. Nitto Denko Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (US$ Million), Price (USD/K Units) and Gross Margin (2019-2024)
    Table 85. Nitto Denko Transdermal Therapeutic Systems (TTS) Product Offerings
    Table 86. Nitto Denko Recent Development
    Table 87. Johnson & Johnson Company Information
    Table 88. Johnson & Johnson Introduction and Business Overview
    Table 89. Johnson & Johnson Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (US$ Million), Price (USD/K Units) and Gross Margin (2019-2024)
    Table 90. Johnson & Johnson Transdermal Therapeutic Systems (TTS) Product Offerings
    Table 91. Johnson & Johnson Recent Development
    Table 92. Lohmann Company Information
    Table 93. Lohmann Introduction and Business Overview
    Table 94. Lohmann Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (US$ Million), Price (USD/K Units) and Gross Margin (2019-2024)
    Table 95. Lohmann Transdermal Therapeutic Systems (TTS) Product Offerings
    Table 96. Lohmann Recent Development
    Table 97. Teikoku Seiyaku Company Information
    Table 98. Teikoku Seiyaku Introduction and Business Overview
    Table 99. Teikoku Seiyaku Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (US$ Million), Price (USD/K Units) and Gross Margin (2019-2024)
    Table 100. Teikoku Seiyaku Transdermal Therapeutic Systems (TTS) Product Offerings
    Table 101. Teikoku Seiyaku Recent Development
    Table 102. Pfizer Company Information
    Table 103. Pfizer Introduction and Business Overview
    Table 104. Pfizer Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (US$ Million), Price (USD/K Units) and Gross Margin (2019-2024)
    Table 105. Pfizer Transdermal Therapeutic Systems (TTS) Product Offerings
    Table 106. Pfizer Recent Development
    Table 107. Bayer Company Information
    Table 108. Bayer Introduction and Business Overview
    Table 109. Bayer Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (US$ Million), Price (USD/K Units) and Gross Margin (2019-2024)
    Table 110. Bayer Transdermal Therapeutic Systems (TTS) Product Offerings
    Table 111. Bayer Recent Development
    Table 112. Lingrui Company Information
    Table 113. Lingrui Introduction and Business Overview
    Table 114. Lingrui Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (US$ Million), Price (USD/K Units) and Gross Margin (2019-2024)
    Table 115. Lingrui Transdermal Therapeutic Systems (TTS) Product Offerings
    Table 116. Lingrui Recent Development
    Table 117. Sanofi Company Information
    Table 118. Sanofi Introduction and Business Overview
    Table 119. Sanofi Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (US$ Million), Price (USD/K Units) and Gross Margin (2019-2024)
    Table 120. Sanofi Transdermal Therapeutic Systems (TTS) Product Offerings
    Table 121. Sanofi Recent Development
    Table 122. UCB Pharma Company Information
    Table 123. UCB Pharma Introduction and Business Overview
    Table 124. UCB Pharma Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (US$ Million), Price (USD/K Units) and Gross Margin (2019-2024)
    Table 125. UCB Pharma Transdermal Therapeutic Systems (TTS) Product Offerings
    Table 126. UCB Pharma Recent Development
    Table 127. Dr. Reddy's Laboratories Company Information
    Table 128. Dr. Reddy's Laboratories Introduction and Business Overview
    Table 129. Dr. Reddy's Laboratories Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (US$ Million), Price (USD/K Units) and Gross Margin (2019-2024)
    Table 130. Dr. Reddy's Laboratories Transdermal Therapeutic Systems (TTS) Product Offerings
    Table 131. Dr. Reddy's Laboratories Recent Development
    Table 132. Qizheng Company Information
    Table 133. Qizheng Introduction and Business Overview
    Table 134. Qizheng Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (US$ Million), Price (USD/K Units) and Gross Margin (2019-2024)
    Table 135. Qizheng Transdermal Therapeutic Systems (TTS) Product Offerings
    Table 136. Qizheng Recent Development
    Table 137. Endo Company Information
    Table 138. Endo Introduction and Business Overview
    Table 139. Endo Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (US$ Million), Price (USD/K Units) and Gross Margin (2019-2024)
    Table 140. Endo Transdermal Therapeutic Systems (TTS) Product Offerings
    Table 141. Endo Recent Development
    Table 142. Mundipharma Company Information
    Table 143. Mundipharma Introduction and Business Overview
    Table 144. Mundipharma Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (US$ Million), Price (USD/K Units) and Gross Margin (2019-2024)
    Table 145. Mundipharma Transdermal Therapeutic Systems (TTS) Product Offerings
    Table 146. Mundipharma Recent Development
    Table 147. Huarun 999 Company Information
    Table 148. Huarun 999 Introduction and Business Overview
    Table 149. Huarun 999 Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (US$ Million), Price (USD/K Units) and Gross Margin (2019-2024)
    Table 150. Huarun 999 Transdermal Therapeutic Systems (TTS) Product Offerings
    Table 151. Huarun 999 Recent Development
    Table 152. Haw Par Company Information
    Table 153. Haw Par Introduction and Business Overview
    Table 154. Haw Par Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (US$ Million), Price (USD/K Units) and Gross Margin (2019-2024)
    Table 155. Haw Par Transdermal Therapeutic Systems (TTS) Product Offerings
    Table 156. Haw Par Recent Development
    Table 157. Nichiban Company Information
    Table 158. Nichiban Introduction and Business Overview
    Table 159. Nichiban Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (US$ Million), Price (USD/K Units) and Gross Margin (2019-2024)
    Table 160. Nichiban Transdermal Therapeutic Systems (TTS) Product Offerings
    Table 161. Nichiban Recent Development
    Table 162. Mentholatum Company Company Information
    Table 163. Mentholatum Company Introduction and Business Overview
    Table 164. Mentholatum Company Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (US$ Million), Price (USD/K Units) and Gross Margin (2019-2024)
    Table 165. Mentholatum Company Transdermal Therapeutic Systems (TTS) Product Offerings
    Table 166. Mentholatum Company Recent Development
    Table 167. Laboratoires Genevrier Company Information
    Table 168. Laboratoires Genevrier Introduction and Business Overview
    Table 169. Laboratoires Genevrier Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (US$ Million), Price (USD/K Units) and Gross Margin (2019-2024)
    Table 170. Laboratoires Genevrier Transdermal Therapeutic Systems (TTS) Product Offerings
    Table 171. Laboratoires Genevrier Recent Development
    Table 172. Beijing Tide Pharmaceutical Company Information
    Table 173. Beijing Tide Pharmaceutical Introduction and Business Overview
    Table 174. Beijing Tide Pharmaceutical Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (US$ Million), Price (USD/K Units) and Gross Margin (2019-2024)
    Table 175. Beijing Tide Pharmaceutical Transdermal Therapeutic Systems (TTS) Product Offerings
    Table 176. Beijing Tide Pharmaceutical Recent Development
    Table 177. Luye Pharma Group Introduction and Business Overview
    Table 178. Luye Pharma Group Transdermal Therapeutic Systems (TTS) Sales (M Units), Revenue (US$ Million), Price (USD/K Units) and Gross Margin (2019-2024)
    Table 179. Luye Pharma Group Transdermal Therapeutic Systems (TTS) Product Offerings
    Table 180. Luye Pharma Group Recent Development
    Table 181. Luye Pharma Group Company Information
    Table 182. Key Raw Materials Lists
    Table 183. Raw Materials Key Suppliers Lists
    Table 184. Transdermal Therapeutic Systems (TTS) Downstream Customers
    Table 185. Transdermal Therapeutic Systems (TTS) Distributors List
    Table 186. Research Programs/Design for This Report
    Table 187. Key Data Information from Secondary Sources
    Table 188. Key Data Information from Primary Sources
List of Figures
    Figure 1. Transdermal Therapeutic Systems (TTS) Product Picture
    Figure 2. Global Transdermal Therapeutic Systems (TTS) Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Transdermal Therapeutic Systems (TTS) Sales Value (2019-2030) & (US$ Million)
    Figure 4. Global Transdermal Therapeutic Systems (TTS) Sales Volume (2019-2030) & (M Units)
    Figure 5. Global Transdermal Therapeutic Systems (TTS) Sales Price (2019-2030) & (USD/K Units)
    Figure 6. Transdermal Therapeutic Systems (TTS) Report Years Considered
    Figure 7. Global Transdermal Therapeutic Systems (TTS) Players Revenue Ranking (2023) & (US$ Million)
    Figure 8. Global Transdermal Therapeutic Systems (TTS) Players Sales Volume Ranking (2023) & (M Units)
    Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Transdermal Therapeutic Systems (TTS) Revenue in 2023
    Figure 10. Transdermal Therapeutic Systems (TTS) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 11. Methyl Salicylate Picture
    Figure 12. Nitroglycerin Picture
    Figure 13. Fentanyl Picture
    Figure 14. Nicotine Picture
    Figure 15. Rivastigmine Picture
    Figure 16. Estradiol Picture
    Figure 17. Others Picture
    Figure 18. Global Transdermal Therapeutic Systems (TTS) Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 19. Global Transdermal Therapeutic Systems (TTS) Sales Value Market Share by Type, 2023 & 2030
    Figure 20. Global Transdermal Therapeutic Systems (TTS) Sales Volume by Type (2019 VS 2023 VS 2030) & (M Units)
    Figure 21. Global Transdermal Therapeutic Systems (TTS) Sales Volume Market Share by Type, 2023 & 2030
    Figure 22. Global Transdermal Therapeutic Systems (TTS) Price by Type (2019-2030) & (USD/K Units)
    Figure 23. Product Picture of OTC Channel
    Figure 24. Product Picture of Retail Channel
    Figure 25. Product Picture of E-Commerce Channel
    Figure 26. Global Transdermal Therapeutic Systems (TTS) Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 27. Global Transdermal Therapeutic Systems (TTS) Sales Value Market Share by Application, 2023 & 2030
    Figure 28. Global Transdermal Therapeutic Systems (TTS) Sales Volume by Application (2019 VS 2023 VS 2030) & (M Units)
    Figure 29. Global Transdermal Therapeutic Systems (TTS) Sales Volume Market Share by Application, 2023 & 2030
    Figure 30. Global Transdermal Therapeutic Systems (TTS) Price by Application (2019-2030) & (USD/K Units)
    Figure 31. North America Transdermal Therapeutic Systems (TTS) Sales Value (2019-2030) & (US$ Million)
    Figure 32. North America Transdermal Therapeutic Systems (TTS) Sales Value by Country (%), 2023 VS 2030
    Figure 33. Europe Transdermal Therapeutic Systems (TTS) Sales Value (2019-2030) & (US$ Million)
    Figure 34. Europe Transdermal Therapeutic Systems (TTS) Sales Value by Country (%), 2023 VS 2030
    Figure 35. Asia Pacific Transdermal Therapeutic Systems (TTS) Sales Value (2019-2030) & (US$ Million)
    Figure 36. Asia Pacific Transdermal Therapeutic Systems (TTS) Sales Value by Country (%), 2023 VS 2030
    Figure 37. South America Transdermal Therapeutic Systems (TTS) Sales Value (2019-2030) & (US$ Million)
    Figure 38. South America Transdermal Therapeutic Systems (TTS) Sales Value by Country (%), 2023 VS 2030
    Figure 39. Middle East & Africa Transdermal Therapeutic Systems (TTS) Sales Value (2019-2030) & (US$ Million)
    Figure 40. Middle East & Africa Transdermal Therapeutic Systems (TTS) Sales Value by Country (%), 2023 VS 2030
    Figure 41. Key Countries/Regions Transdermal Therapeutic Systems (TTS) Sales Value (%), (2019-2030)
    Figure 42. Key Countries/Regions Transdermal Therapeutic Systems (TTS) Sales Volume (%), (2019-2030)
    Figure 43. United States Transdermal Therapeutic Systems (TTS) Sales Value, (2019-2030) & (US$ Million)
    Figure 44. United States Transdermal Therapeutic Systems (TTS) Sales Value by Type (%), 2023 VS 2030
    Figure 45. United States Transdermal Therapeutic Systems (TTS) Sales Value by Application (%), 2023 VS 2030
    Figure 46. Europe Transdermal Therapeutic Systems (TTS) Sales Value, (2019-2030) & (US$ Million)
    Figure 47. Europe Transdermal Therapeutic Systems (TTS) Sales Value by Type (%), 2023 VS 2030
    Figure 48. Europe Transdermal Therapeutic Systems (TTS) Sales Value by Application (%), 2023 VS 2030
    Figure 49. China Transdermal Therapeutic Systems (TTS) Sales Value, (2019-2030) & (US$ Million)
    Figure 50. China Transdermal Therapeutic Systems (TTS) Sales Value by Type (%), 2023 VS 2030
    Figure 51. China Transdermal Therapeutic Systems (TTS) Sales Value by Application (%), 2023 VS 2030
    Figure 52. Japan Transdermal Therapeutic Systems (TTS) Sales Value, (2019-2030) & (US$ Million)
    Figure 53. Japan Transdermal Therapeutic Systems (TTS) Sales Value by Type (%), 2023 VS 2030
    Figure 54. Japan Transdermal Therapeutic Systems (TTS) Sales Value by Application (%), 2023 VS 2030
    Figure 55. South Korea Transdermal Therapeutic Systems (TTS) Sales Value, (2019-2030) & (US$ Million)
    Figure 56. South Korea Transdermal Therapeutic Systems (TTS) Sales Value by Type (%), 2023 VS 2030
    Figure 57. South Korea Transdermal Therapeutic Systems (TTS) Sales Value by Application (%), 2023 VS 2030
    Figure 58. Southeast Asia Transdermal Therapeutic Systems (TTS) Sales Value, (2019-2030) & (US$ Million)
    Figure 59. Southeast Asia Transdermal Therapeutic Systems (TTS) Sales Value by Type (%), 2023 VS 2030
    Figure 60. Southeast Asia Transdermal Therapeutic Systems (TTS) Sales Value by Application (%), 2023 VS 2030
    Figure 61. India Transdermal Therapeutic Systems (TTS) Sales Value, (2019-2030) & (US$ Million)
    Figure 62. India Transdermal Therapeutic Systems (TTS) Sales Value by Type (%), 2023 VS 2030
    Figure 63. India Transdermal Therapeutic Systems (TTS) Sales Value by Application (%), 2023 VS 2030
    Figure 64. Transdermal Therapeutic Systems (TTS) Industrial Chain
    Figure 65. Transdermal Therapeutic Systems (TTS) Manufacturing Cost Structure
    Figure 66. Channels of Distribution (Direct Sales, and Distribution)
    Figure 67. Bottom-up and Top-down Approaches for This Report
    Figure 68. Data Triangulation
    Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Drugs to Treat Hypertriglyceridemia - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-37P13132
Wed Nov 06 00:00:00 UTC 2024

Add to Cart

Medications for Canine Atopic Dermatitis - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-13T13744
Wed Nov 06 00:00:00 UTC 2024

Add to Cart

Medications for Actinic Keratosis - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-36R13742
Wed Nov 06 00:00:00 UTC 2024

Add to Cart

Melatonin API - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-21J13714
Wed Nov 06 00:00:00 UTC 2024

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions